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 IN VITRO FERTILIZATION AND THE LAW: 
HOW LEGAL AND REGULATORY NEGLECT 
COMPROMISED A MEDICAL BREAKTHROUGH 
Steve P. Calandrillo* and Chryssa V. Deliganis** 
The rise of assisted reproductive technology like in vitro fertilization (“IVF”) as a 
method of human reproduction represents a remarkable medical achievement. Live 
births and success rates have increased dramatically in the past decade, so much 
so that many fertility clinics now “guarantee” a baby to clients who sign up. But 
with successes come inevitable downsides. Everyone knows that the price tag is 
steep, but given the demand, relatively few individuals are deterred. More 
insidious are the increased birth-defect risks associated with reproductive 
technologies. For some time it was assumed that these risks were due to the fact 
that individuals attempting IVF were older and possessed greater risk factors 
themselves. Now, however, recent research is showing that it may be IVF itself, 
and, in particular, the dramatic rise of a new technique called intracytoplasmic 
sperm injection (“ICSI”), that is responsible for negative outcomes. IVF providers 
face little incentive to impress these risks on their customers, and operate in a 
largely unregulated environment in which cash is king and informed consent is 
optional. The incentive to report high live-birth rates dictated by the profit motive 
pushes some clinics to implant more embryos than necessary and to recommend 
technologies that may increase births despite the fact that they increase defect 
rates. 
Sadly, law and regulation lag far behind the technology in this arena. While some 
industry groups have promulgated responsible guidelines for appropriate use of 
reproductive technology, they come with no viable enforcement or disciplinary 
mechanisms. Law’s absence has contributed to a “wild west” mentality in some 
fertility clinics, where anything goes if it will make money. It is past time that the 
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law and medical regulators become involved in assessing the rapidly growing 
reproductive technologies available today in order to preserve their benefits while 
mitigating the risks that are largely unknown or ignored by most patients. 
TABLE OF CONTENTS 
INTRODUCTION ..................................................................................................... 312 
I. THE REMARKABLE HISTORY OF ASSISTED REPRODUCTION .............................. 313 
A. Early Discoveries ....................................................................................... 314 
B. Dramatic Explosion in ART Technology During the 1980s ...................... 315 
C. Addressing Male Infertility: ICSI and IVF ................................................ 316 
D. Remarkable Outcomes (and Expenses) ...................................................... 317 
II. THE DOWNSIDE OF SUCCESS ............................................................................ 320 
A. The Dangers of Assisted Reproduction: Fertility Drugs and the Risk of 
Multiples .................................................................................................. 320 
B. The Dangers of IVF and ICSI: Birth Defects and Genetic Considerations 324 
III. CURRENT LEGAL AND REGULATORY OVERSIGHT OF ASSISTED REPRODUCTIVE 
TECHNOLOGY .............................................................................................. 329 
A. Regulations Barely Exist and Voluntary Guidelines Do Not Work ........... 329 
B. Foreign Approaches ................................................................................... 333 
IV. RECOMMENDATIONS FOR LAW AND POLICY REFORM .................................... 336 
A. Dealing with Complications Raised by Multiples ...................................... 336 
B. Influencing the Choice of ART Method ..................................................... 337 
C. A Measured Regulatory Response ............................................................. 337 
D. Mandated Disclosure and the Regulation of ICSI ...................................... 338 
E. Moving Forward into the Future ................................................................ 340 
1. Federal Oversight ................................................................................... 340 
2. Mandatory Clinic Certification ............................................................... 341 
CONCLUSION ........................................................................................................ 342 
 
INTRODUCTION 
A remarkable transformation in human reproduction is underway in our 
society. For all of human history, there was but one tried-and-true method 
available to individuals who wished to be parents. Today, however, extraordinary 
pharmaceutical and technological innovation is fundamentally changing the way 
Americans have children. The technology continues to expand by leaps and 
bounds every year, while law and governmental regulation lag far behind. From 
fertility drugs, to intra-uterine insemination, to the advent of in vitro fertilization 
(“IVF”), and now intracytoplasmic sperm injection (“ICSI”), modern medicine has 
paved the way for millions of Americans to have children who were previously 
only the subject of their unrequited dreams. 
Obviously, these transformational reproductive breakthroughs have 
provided immeasurable joy for new parents. Today, ten million children are alive 
who could not have been born just one generation ago. 
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However, these new innovations and technologies carry their own unique 
risks, from multiple births to low birth weight to severe birth defects. Yet these 
inherent dangers are often glossed over by a fertility industry now making billions 
of dollars per year. The perverse financial incentives, paired with the pressure for 
reproductive clinics to advertise better outcomes (i.e., live births), have led some to 
engage in practices that are not only questionable, but that are sometimes even 
quite dangerous for their patients. 
Why are these risks and dangers becoming exponentially worse today? 
Quite candidly, it is the stunning absence of law and regulation in the medical 
reproductive arena. Technological advances have greatly outpaced the introduction 
of responsible laws and regulation. Politicians will not touch the controversial 
subject with a ten-foot pole, and federal funding of embryo research is explicitly 
banned. Not surprisingly, government regulators have therefore been largely 
uninvolved and ineffective in the field. Further, the reproductive professionals 
themselves resist all forms of outside interference, fearing that their skyrocketing 
profits might be in danger. They cry, “We can regulate ourselves—keep law out!” 
But we all know what happens when the fox guards the hen house. 
Part I of this Article details the historical background of fertility 
treatments, ranging from pharmaceutical breakthroughs to intrauterine 
insemination to IVF and now ICSI. Part II explores the downsides of fertility 
treatments’ unparalleled “success,” and, in particular, examines the hidden dangers 
of fertility drugs, the risk of multiple births, birth defects, and the unique 
challenges posed by IVF and ICSI. The “wild west” mentality of the industry has 
even prompted the inventor of the latter technique to publicly criticize its dramatic 
overuse. Part III lays out the current legal and regulatory oversight scheme in the 
United States, paying attention to the enormous gaps in coverage, the lack of 
enforcement mechanisms, and the consequences for patients. Part IV offers 
normative recommendations for legal and public policy reform, including 
mandated disclosure of risks, mandatory certification of fertility clinics, and the 
explicit federal regulation of IVF and ICSI. Adopting these legal and regulatory 
approaches allows for the ability to maintain the benefits of these amazing new 
reproductive innovations, while also preventing future abuses. 
In sum, it is past time for legislatures and regulators to address the unique 
benefits and challenges created by the rise of modern reproductive technologies. If 
we fail to muster the political will to do so today, thousands of future lives will 
suffer as a result. 
I. THE REMARKABLE HISTORY OF ASSISTED REPRODUCTION 
For many people, starting a family is the most fulfilling and important 
task they will ever undertake—an intimate act central to realizing one’s life goals. 
However, biology is not always kind. For all of human history, countless millions 
of people have been unable to have children. Today, however, assisted 
reproductive technology has opened the doors of parenthood to millions for whom 
those doors were once firmly shut.  
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A. Early Discoveries 
Modern assisted reproductive technology (“ART”) is the culmination of 
over 100 years of research and experimentation. As early as 1878, researchers 
began attempts to fertilize mammalian eggs in vitro.1 These early attempts were 
largely unsuccessful, and although the possibility that fertilization occurred in 
some cases has not been ruled out, most early claims of success were inadequately 
substantiated or based on misinterpreted results.2 However, a major breakthrough 
in IVF experimentation came in 1951 with the discovery of sperm capacitation by 
Colin Russell Austin and Min Chueh Chang.3 Capacitation refers to changes that 
sperm undergo prior to fertilization while residing in a female’s reproductive 
tract.4 Within a few years of their discovery, researchers successfully fertilized 
rabbit eggs in vitro for the first time.5 During the “golden age” of IVF research that 
followed, numerous experiments were conducted on a wide range of mammal 
species,6 culminating in 1969 with the first convincing fertilization of human eggs 
in vitro.7 The achievement was made possible by research done on hamster IVF 
that allowed for the proper modification of culture-medium protocols.8 However, 
despite researchers’ success in fertilizing eggs in vitro, it would be nearly another 
decade before in vitro resulted in a live birth.9 
In July 1978, Louise Brown became the first person born as a result of 
IVF.10 Her mother, Lesley Brown, had enlisted the aid of Patrick Steptoe and 
                                                                                                                
 1. Barry D. Bavister, Early History of In Vitro Fertilization, 124 REPROD. 181, 
182 (2002) (In vitro essentially means in glass, or in other words, in the laboratory. This is 
contrasted with in vivo, which means inside a living organism). 
 2. Id. at 182–83. 
 3. Id. at 183 (“Both Austin and Chang postulated that the spermatozoa of some 
mammalian species need to reside for some time with the female reproductive tract before 
acquiring the capacity to penetrate eggs, and Austin (1951) coined the term ‘capacitation’ to 
refer to the change spermatozoa undergo during this time.”); see also C.R. Austin, 
Observations on the Penetration of Sperm into the Mammalian Egg, 4 AUSTL. J. SCI. 
RESEARCH SERIES B 581 (1951); M.C. Chang, Fertilizing Capacity of Spermatozoa 
Deposited into the Fallopian Tubes, 168 NATURE 697 (1951). 
 4. Bavister, supra note 1, at 183. 
 5. Id. 
 6. Id. at 183–84 (IVF research was performed with hamsters, mice, rats, sheep, 
pigs, and cats). 
 7. Id. at 184 (Fertilization of human eggs in vitro was first “convincingly 
achieved in 1969, as evidenced by sperm penetration, polar body emission and formation of 
pronuclei.” (citing B.D. Bavister et al., Identification of the Midpiece and Tail of the 
Spermatozoon During Fertilisation of Human Eggs In Vitro, 20 J. REPROD. & FERTILITY 159 
(1969))). 
 8. Id. at 183–84 (“[I]t may be claimed that hamster IVF paved the way for 
human IVF.” (citing R. Yanagimachi & M.C. Chang, Fertilisation of Hamster Eggs In 
Vitro, 200 NATURE 281 (1963); R. Yanagimachi & M.C. Chang, In Vitro Fertilisation of 
Golden Hamster Ova, 156 J. EXPERIMENTAL ZOOLOGY 361 (1964))). 
 9. Bavister, supra note 1, at 184 (the first human birth from an IVF embryo 
occurred in 1978). 
 10. Jeff Wang & Mark V. Sauer, In Vitro Fertilization (IVF): A Review of 3 
Decades of Clinical Innovation and Technological Advancement, 2 THERAPEUTICS & 
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Robert Edwards at Oldham General Hospital in England in an attempt to overcome 
her persistent infertility.11 The successful procedure involved laparoscopic surgery 
to retrieve one of her eggs, which was then fertilized in a laboratory, and later 
transferred back into the uterus.12 This original procedure did not utilize any 
fertility drugs.13 Steptoe and Edwards went on not only to repeat this result 
successfully in future experiments, but also substantially improved their technique 
over the next several years.14 
B. Dramatic Explosion in ART Technology During the 1980s 
The 1980s witnessed dramatic growth and advancement in assisted 
reproductive technologies. Between 1980 and 1983, the widespread use of fertility 
drugs such as clomiphene15 and leuprorelin16 in the IVF process drastically 
improved the pregnancy rate by 6%–30% per cycle.17 By the mid-1980s, several 
alternative methods of assisted reproduction came to fruition, including gamete 
intrafallopian transfer (“GIFT”) and zygote intrafallopian transfer (“ZIFT”).18 
These procedures differed from IVF in a number of ways. GIFT involves 
fertilization in vivo—in other words, within the woman’s reproductive tract rather 
than in a laboratory.19 ZIFT was similar to traditional IVF but also involved a 
                                                                                                                
CLINICAL RISK MGMT. 355, 356 (2006); see also P.C. Steptoe & R.G. Edwards, Birth After 
Reimplantation of a Human Embryo, 312 LANCET 366, 366 (1978). 
 11. Wang & Sauer, supra note 10. 
 12. Id. (citing Steptoe & Edwards, supra note 10). 
 13. Id. (noting that no medications were used to “stimulate the ovaries” of Lesley 
Brown prior to laparoscopic egg retrieval). 
 14. Id. 
 15. Commonly marketed as Clomid, clomiphene has been around since the 
1960s and has long been used to treat ovulatory dysfunction in women desiring a 
pregnancy. In a clinical study of over 7,000 patients suffering from impediments to 
ovulation, administration of Clomid resulted in a roughly 30% pregnancy rate. Of those 
pregnancies, about 8% were multiple. See Clomid FDA label, U.S. FOOD & DRUG ADMIN. 
(Nov. 22, 2012), http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016131s02
6lbl.pdf. 
 16. Commonly marketed as Lupron, leuprorelin is indicated to treat female 
fertility conditions such as Endometriosis and Uterine Leiomyomata. See Lupron FDA 
Label, U.S. FOOD & DRUG ADMIN. (Nov. 30, 2013), http://www.accessdata.fda.gov/ 
drugsatfda_docs/label/2012/ 016131s026lbl.pdf. However, it should be noted that the drug 
is contraindicated for women who may become pregnant while using the drug due to 
potential harm to the fetus. Id. (“LUPRON DEPOT may cause fetal harm when 
administered to a pregnant woman.”). 
 17. Id.; see also R.G. Edwards & P.C. Steptoe, Current Status of In-Vitro 
Fertilisation and Implantation of Human Embryos, 2 LANCET 1265 (1983). 
 18. Wang & Sauer, supra note 10, at 357. 
 19. STEVE PARKER, IN VITRO FERTILIZATION 33 (2007) (“In this technique, eggs 
and sperm . . . are collected and checked as in a standard IVF procedure. But instead of 
placing the eggs and sperm into a culture medium, they are put back into the woman’s 
fallopian tube using a laparoscope. Fertilization then takes place in the fallopian tube, as 
happens in natural conceptions.”). 
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second laparoscopy to transfer the fertilized egg into the fallopian tube.20 Both 
procedures offered advantages over the original IVF method developed by Steptoe 
and Edwards. 
However, IVF soon returned to the forefront of reproductive technology 
due to major breakthroughs in ultrasound technology in the late 1980s. These 
improvements transformed the process of oocyte retrieval into the modern 
outpatient IVF procedure we know today. In 1987 the development of ultrasound-
guided transvaginal follicle aspiration created numerous advances over its 
predecessor techniques, and quickly became the “procedure of choice.”21 The 
innovation did away with the necessity of laparoscopy, and in turn decreased the 
time, expense, and risk involved in the oocyte retrieval process.22 The 
improvement was so substantial that IVF procedures transitioned from one or two 
hours of hospital-based operating-room time to a mere 10 or 15 minute process 
that could be performed in an office setting.23 The dramatic improvement in 
ultrasound technology marginalized GIFT and ZIFT, as those procedures 
continued to necessitate invasive surgery.24 In contrast, IVF could now be 
performed without laparoscopy, and instead utilized less expensive and minimally 
invasive ultrasound-guided aspirations.25 Thus, despite a lower pregnancy rate per 
procedure, by the early to mid-1990s IVF had become firmly ensconced as the 
preferred method of assisted reproduction and has remained so ever since.26 
C. Addressing Male Infertility: ICSI and IVF 
While traditional IVF was often successful in treating female infertility, 
the overall effectiveness of the procedure was limited by its inability to adequately 
address male infertility.27 However, the male end of the fertility equation was soon 
addressed. In 1992 researchers introduced a new procedure, known as ICSI, 
                                                                                                                
 20. Id.; see also Wang & Sauer, supra note 10, at 357 (explaining that ZIFT 
allowed for the confirmation of fertilization while maintaining some of the theoretical 
benefits of GIFT but that the procedure required two laparoscopies to complete). 
 21. Wang & Sauer, supra note 10, at 358 (“First reported in 1987, this oocyte 
retrieval technique quickly became the procedure of choice due to better visualization, finer 
control, and less patient discomfort compared with other available methods.” (citing Matts 
Wikland et al., Use of a Vaginal Transducer for Oocyte Retrieval in an IVF/ET Program, 
15 J. CLINICAL ULTRASOUND 245 (1987))). 
 22. Id. 
 23. Id. 
 24. Id. 
 25. Id. 
 26. Id. at 358–59 (“By 1995, Society for Assisted Reproductive Technology 
(SART) data noted that IVF, GIFT, and ZIFT consisted of 70%, 6%, and 2% of ART cycles 
respectively, despite pregnancy rates of 22.3%, 28.7%, and 30.3% for each procedure. . . . 
In 2003, GIFT and ZIFT were used in only 0.1% and 0.4% of ART cycles, while IVF 
represented the remaining 99.5% of cases.”); see also CTRS. FOR DISEASE CONTROL & 
PREVENTION, ASSISTED REPRODUCTIVE TECHNOLOGY REPORT: NATIONAL ART SUCCESS 
RATES (2003), http://nccd.cdc.gov/DRH_ ART/Apps/NationalSummaryReport.aspx (select 
“2003” from the drop-down menu at the top of the page). 
 27. Wang & Sauer, supra note 10, at 359. 
2015] IVF AND THE LAW 317 
designed to address many of the challenges posed by male infertility.28 ICSI differs 
from traditional IVF in that, instead of letting the sperm and eggs mingle freely in 
order to achieve conception, a single sperm is isolated and injected directly into the 
cytoplasm of the egg with a microneedle.29 Because the procedure requires only a 
single healthy sperm, it is especially useful to treat infertility in a man who suffers 
from a low sperm count or the presence of abnormal sperm (e.g., those that cannot 
“swim” on their own).30 The development of testicular sperm extraction (“TESE”) 
has allowed fertilization rates of up to 70%, despite using only a few poor-quality 
sperm.31 
After its introduction, ICSI quickly gained popularity, rapidly 
transitioning into clinical practice and accounting for 11% of all IVF cycles by 
1995.32 Moreover, the popularity of ICSI has continued to expand rapidly—in 
2011 the procedure accounted for a shocking 67% of all IVF cycles.33 However, 
Jeff Wang and Mark Sauer note that there is still a significant debate on the 
propriety of “altering the process of natural selection” so drastically, since ICSI 
allows potentially poor-quality sperm to fertilize eggs that never would have had a 
chance before its invention.34 
D. Remarkable Outcomes (and Expenses) 
Today IVF is practiced in a majority of the world’s countries,35 and since 
its inception, the procedure is estimated to be responsible for the birth of around 
ten million babies.36 In the United States, roughly 10% of Americans suffer from 
some kind of fertility problem leading approximately one million people to seek 
fertility treatment annually.37 The revenue generated by this market activity is 
immense—IVF is a costly procedure with a single cycle of treatment costing 
$10,000–$20,000.38 What’s more, because IVF is not always successful in 
                                                                                                                
 28. Id. (citing Gianpiero Palermo et al., Pregnancies After Intracytoplasmic 
Injection of Single Spermatozoon into an Oocyte, 340 LANCET 17, 17–18 (1992)). 
 29. See PARKER, supra note 19, at 32. 
 30. Id. 
 31. Wang & Sauer, supra note 10, at 359. 
 32. Id. (citing CTRS. FOR DISEASE CONTROL & PREVENTION, ASSISTED 
REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY CLINICS 
REPORT (1995)). 
 33. CTRS. FOR DISEASE CONTROL & PREVENTION, ASSISTED REPRODUCTIVE 
TECHNOLOGY REPORT: NATIONAL ART SUCCESS RATES 4 (2011), available at 
http://www.cdc.gov/art/pdf/2011-report/national-summary/art-2011-national-summary-
report.pdf [hereinafter 2011 ART REPORT]. 
 34. Wang & Sauer, supra note 10, at 359–60 (discussing inheritable causes of 
male infertility, their transmission via ICSI, and the potential for increased health problems 
in children conceived via ICSI); see also discussion infra Part II. 
 35. KAY ELDER & BRIAN DALE, IN-VITRO FERTILIZATION viii (3d ed. 2011). 
 36. Id. 
 37. NAOMI R. CAHN, TEST TUBE FAMILIES: WHY THE FERTILITY MARKET NEEDS 
LEGAL REGULATION 1 (2009). 
 38. CHARLES P. KINDREGAN JR. & MAUREEN MCBRIEN, ASSISTED REPRODUCTIVE 
TECHNOLOGY: A LAWYER’S GUIDE TO EMERGING LAW AND SCIENCE 95 (2d ed. 2011) (citing 
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producing a pregnancy, many patients have to undergo multiple procedures, 
significantly raising the overall cost and risk of treatment.39 The fertility industry 
has grown to accommodate this demand—with nearly 500 clinics in existence 
nationwide, fertility drugs alone make up a $3 billion per year industry.40 In light 
of the incredible cost for what is essentially an elective procedure, it should not 
come as a surprise that insurance coverage for IVF is limited or nonexistent in 
most states.41 
As the industry has grown, the use of artificial reproductive technology, 
including both IVF and pharmaceutical interventions, has steadily increased.42 In 
1996 there were nearly 65,000 ART cycles resulting in 14,507 live-birth deliveries 
for a total of 20,840 live-born infants.43 By 2011 the number of ART cycles had 
more than doubled to over 150,000, resulting in 47,818 live births for a total of 
61,610 live-born infants.44 Moreover, as the usage of IVF has increased, so has the 
prevalence of ICSI—in 2011 ICSI accounted for 67% of all ART cycles.45 This 
represents a dramatic increase in the use of a procedure that 16 years ago 
accounted for only 11% of all IVF procedures.46 In fact, the percentage of IVF 
cycles utilizing ICSI has increased every single year from 1997 to 2011.47 
The explosion in ICSI’s popularity also tracks a dramatic uptick in the 
success rate of IVF. According to the Centers for Disease Control and Prevention 
(“CDC”), in 1997 30.7% of IVF cycles resulted in live births for mothers under the 
age of 35.48 In that year, ICSI was used in only 35% of all IVF cycles.49 In 
contrast, by 2010 41.5% of all IVF cycles resulted in live births for mothers under 
the age of 35—with ICSI being used in 66% of all IVF cycles.50 The trend holds 
true for all of the surveyed age groups: as the percentage of IVF cycles utilizing 
                                                                                                                
Judith F. Darr, Accessing Reproductive Technologies: Invisible Barriers, Indelible Harms, 
23 BERKELEY J. GENDER L. & JUST. 18, 36 n.64 (2008)). 
 39. See id. 
 40. CAHN, supra note 37. 
 41. KINDREGAN & MCBRIEN, supra note 38 (citing Judith F. Darr, Accessing 
Reproductive Technologies: Invisible Barriers, Indelible Harms, 23 BERKELEY J. GENDER L. 
& JUST. 18, 36 n.64 (2008)). 
 42. See CAHN, supra note 37. 
 43. CTRS. FOR DISEASE CONTROL & PREVENTION, ASSISTED REPRODUCTIVE 
TECHNOLOGY REPORT: NATIONAL SUMMARY AND FERTILITY CLINICS SUCCESS RATES (1996). 
 44. 2011 ART REPORT, supra note 33, at 3. 
 45. Id. at 4. 
 46. Wang & Sauer, supra note 10, at 359 (citing NAT’L CTR. FOR CHRONIC 
DISEASE PREVENTION & HEALTH PROMOTION, 2003 ASSISTED REPRODUCTIVE TECHNOLOGY 
SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY CLINIC REPORTS (2005)). 
 47. See CTRS. FOR DISEASE CONTROL & PREVENTION, ASSISTED REPRODUCTIVE 
TECHNOLOGY REPORT: NATIONAL SUMMARY AND FERTILITY CLINICS SUCCESS RATES (1997), 
available at http://nccd.cdc.gov/DRH_ART/Apps/NationalSummaryReport.aspx 
[hereinafter 1997 ART REPORT]; CTRS. FOR DISEASE CONTROL & PREVENTION, ASSISTED 
REPRODUCTIVE TECHNOLOGY REPORT: NATIONAL SUMMARY AND FERTILITY CLINICS 
SUCCESS RATES (2010) [hereinafter 2010 ART REPORT], available at 
http://www.cdc.gov/art/ART2010/#report1. 
 48. 1997 ART REPORT, supra note 47. 
 49. Id. 
 50. 2010 ART REPORT, supra note 47. 
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ICSI has increased, so has the percentage of cycles resulting in live births.51 This 
trend is particularly pronounced among older women. In 1997 only 7.6% of IVF 
cycles resulted in live births for women aged 41–42.52 By 2010, the live-birth rate 
had risen to 12.4% for women in this age group—a 63% increase.53 
The data shows several unmistakable trends over the last 15 years: (1) the 
percentage of IVF cycles utilizing ICSI increased dramatically; (2) the percentage 
of IVF cycles that led to live births increased almost every single year; and (3) the 
percentage of successful outcomes for older mothers increased substantially.54 
Many of the genetic factors that prohibited spontaneous reproduction in both sexes 
have now been overcome by traditional IVF and ICSI.55 The inevitable tick of the 
biological clock is no longer the same barrier it once was to older women.56 In the 
words of one commentator, “Creating a family, regardless of whether you are an 
infertile husband-and-wife couple, a same-sex couple, or a single person, now 
involves a deliberate choice.”57 
However, it should be noted that all of the successes detailed above offer 
no glimpse into patient outcomes after a live birth has occurred. As with every 
pioneering technology, there are inevitable downsides, some of which may not be 
immediately apparent. 
                                                                                                                
 51. See supra text accompanying note 47 (data from 1997–2011 shows 
consistent upward trend in success rates and usage of ICSI). 
 52. 1997 ART REPORT, supra note 47 (data from 1997 shows 6,691 IVF cycles 
performed on women aged 41–42 with a success rate of 7.6%). 
 53. 2010 ART REPORT, supra note 47 (data from 2010 shows 10,122 cycles 
performed on women aged 41–42 with a success rate of 12.4%). 
 54. See supra text accompanying note 47 (data is currently available from 1997–
2011 allowing for the identification of trends within that range). 
 55. See Wang & Sauer, supra note 10, at 362. Moreover, emerging technologies 
such as preimplantation genetic diagnosis (“PGD”) have allowed couples suffering from 
some sex-linked diseases and other genetic disorders to have children free of those 
conditions. See CAHN, supra note 37, at 62. PGD is generally available to screen for several 
kinds of diseases: (1) testing to determine the sex of the embryo for sex-linked diseases like 
Duchenne muscular dystrophy; (2) diseases that result from a single gene defect such as 
cystic fibrosis; and (3) chromosomal disorders. Frances A. Flinter, Preimplantation Genetic 
Diagnosis Needs to Be Tightly Regulated, 322 BRIT. MED. J. 1008, 1008–09 (2001). PGD 
can also be used to screen for aneuploidy (e.g., Down’s Syndrome), though this is not 
allowed in some countries (e.g., the United Kingdom). Id. at 1009. However, for its many 
promising benefits, PGD also has risks. One study found that the procedure has the potential 
to lower the live-birth rate for older women. See Sebastian Mastenbroek et al., 
Preimplantation Genetic Screening: A Systematic Review and Meta-Analysis of RCTs, 17 
HUM. REPROD. UPDATE 454, 454 (2011). Another suggested PGD might be responsible for 
increasing the perinatal death rate in multiple pregnancies. Inge Liebaers et al., Report on a 
Consecutive Series of 581 Children Born After Blastomere Biopsy for Preimplantation 
Genetic Diagnosis, 65 OBSTETRICAL & GYNECOLOGICAL SURV. 240, 240 (2010). 
 56. See CAHN, supra note 37 (noting that by the age of 40, 33% of couples are 
infertile and that 18% of women using ART technology were over the age of 40 in 2004). 
 57. Id. at 3. 
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II. THE DOWNSIDE OF SUCCESS 
While ART has provided millions of couples with the incredible 
opportunity to become parents, emerging research suggests that it comes with 
significant risks for the children produced. The profit motive leads some fertility 
clinics to prescribe drugs that may unnecessarily cause multiple births and 
associated negative health outcomes for both mothers and children. When IVF is 
the reproductive route of choice, some clinics have been known to harvest more 
eggs and implant more embryos than responsible medical providers should. Worse, 
the emerging new IVF technique of choice, ICSI, presents risks that many soon-to-
be parents are wholly unaware of. 
A. The Dangers of Assisted Reproduction: Fertility Drugs and the Risk of 
Multiples 
Assisted reproduction spans a wide range of procedures, each with its 
own benefits and risks. The most widely used “first option” in the assisted 
reproduction field is not IVF or ICSI; rather, fertility drugs—such as Clomid, 
Lupron, Repronex—form the foundation of most modern infertility treatments.58 
These drugs are generally used to stimulate ovulation and allow for the harvesting 
of multiple oocytes.59 The rise of ovulation-stimulation drugs has contributed to a 
rapid increase in the number of high-order pregnancies involving three or more 
fetuses.60 ART-related use of the drugs typically involves the removal of multiple 
eggs after stimulation and then fertilization via either IVF or ICSI.61 In contrast, 
when used without ART, the ovulation drugs are typically used in conjunction 
with timed sexual intercourse, or some other form of assisted insemination such as 
intrauterine insemination (“IUI”).62 Both uses are associated with extremely high 
incidences of multiple gestation and multiple births.63 In fact, roughly 44% of all 
                                                                                                                
 58. See Laura A. Schieve et al., Estimation of the Contribution of Non-assisted 
Reproductive Technology Ovulation Stimulation Fertility Treatments to US Singleton and 
Multiple Births, 170 AM. J. EPIDEMIOLOGY 1396 (2009) (concluding that roughly 4.6% of 
infants born in the U.S. in 2005 resulted from non-ART ovulation treatments, which is four 
times greater than the contribution of ART). 
 59. Reproductive Health, Infertility FAQs, CTRS. FOR DISEASE CONTROL & 
PREVENTION, http://www.cdc.gov/reproductivehealth/Infertility/index.htm (last updated 
June 20, 2013) (discussing the use and purpose of common fertility drugs). 
 60. See Norbert Gleicher et al., Reducing the Risk of High-Order Multiple 
Pregnancy After Ovarian Stimulation with Gonadotropins, 343 NEW ENG. J. MED. 2 (2000); 
Schieve et al., supra note 58, at 1397. 
 61. See Schieve et al., supra note 58. 
 62. Id. Despite the success of IVF, intrauterine insemination remains relatively 
common, often making up the first step before couples resort to the more invasive—and 
expensive—IVF. IUI involves the placement of washed and concentrated sperm directly 
into a woman’s uterus around the time she releases one or more eggs. Tests and 
Procedures: Intrauterine Insemination: Definition, MAYO CLINIC (June 29, 2013), 
http://www.mayoclinic.org/tests-procedures/intrauterine-insemination/ basics/definition/prc-
20018920. The procedure is often undertaken with sperm from an anonymous donor or 
from a known male, often the husband. 
 63. Schieve et al., supra note 58. 
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ART procedures result in twins, and about 5% result in triplets or higher-order 
multiples.64 
While some infertile parents are not overly deterred by the thought of 
having twins or triplets, they are often far less aware that multiple-order 
pregnancies are associated with a dramatically increased risk of substantial health 
problems. Compared to singletons, multiple-order pregnancies are subject to 
markedly higher risks of pregnancy complications, preterm delivery, infant death, 
and neurological impairments in the surviving babies.65 Preterm delivery is 
especially common, as the length of pregnancy decreases significantly with each 
additional fetus. In fact, about 60% of twins, and more than 90% of higher-order 
multiples, are born premature.66 Low birth weight is also common and often results 
from preterm delivery.67 According to data gathered by the CDC, in 2005 97% of 
all triplets or higher-order multiples conceived through ART were born 
premature.68 While advances in preterm care have brightened outlooks for these 
babies somewhat, the costs are extraordinary and the children are still at increased 
risk for early health problems and lasting disabilities like cerebral palsy, hearing 
loss, and intellectual disability.69 Moreover, at least one study has found that 
opposite-sex twins born from non-IVF-controlled ovarian stimulation had a 
significantly higher incidence of very low birth weight and severe prematurity 
compared to opposite-sex twins that were conceived naturally.70 
Singletons and mothers are not entirely immune from the dangers posed 
by ovulation treatments either. Some studies have suggested that singletons 
conceived with the aid of non-ART ovulation treatments may be at increased risk 
of pregnancy complications, low birth weight, preterm delivery, and other poor 
outcomes.71 Mothers also face the risk of health problems associated with carrying 
twins, triplets, or higher-order multiples to term. Especially common is pre-
eclampsia, a complication characterized by high blood pressure, swelling, and 
                                                                                                                
 64. Victoria Clay Wright et al., Assisted Reproductive Technology Surveillance– 
United States, 2005, 57 MORBIDITY & MORTALITY WKLY. REP. SURVEILLANCE SUMMARIES 
1, 8 (2008). 
 65. See Schieve et al., supra note 58; see also Wright et al., supra note 64, at 1. 
 66. See Multiples: Twins, Triplets and Beyond, MARCH OF DIMES (Dec. 2009), 
http://www.marchofdimes.com/pregnancy/multiples-twins-triplets-and-beyond.aspx. 
 67. Id. (“More than half of twins and almost all higher-order multiples are born 
with low birthweight (less than 5½ pounds or 2,500 grams). [Low birth weight] can result 
from premature birth and/or poor fetal growth. Both are common in multiple pregnancies.”). 
 68. See Wright et al., supra note 64, at 1. 
 69. Id. (discussing the health and disability challenges facing low birth weight 
babies). 
 70. Willem Ombelet et al., Perinatal Outcome of 12,021 Singleton and 3,108 
Twin Births After Non-IVF-Assisted Reproduction: A Cohort Study, 21 HUMAN REPROD. 
1025, 1030 (2006). 
 71. Id. (citing Marco Gaudoin et al., Ovulation Induction/Intrauterine 
Insemination in Infertile Couples is Associated with Low-Birth-Weight Infants, 188 AM. J. 
OBSTETRICS & GYNECOLOGY 611 (2003); Bengt Källén et al., Neonatal Outcome in 
Pregnancies from Ovarian Stimulation, 100 OBSTETRICS & GYNECOLOGY 414 (2002); 
Ombelet et al., supra note 70). 
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protein in the urine.72 The condition can be dangerous, in some cases leading to 
seizures, kidney, or liver damage, and can potentially put both the mother’s and 
child’s lives at risk.73 This complication is especially concerning because it may 
occur in as many as 40% of all triplet pregnancies.74 Finally, for many high-order 
pregnancies, obstetricians strongly suggest “multifetal reduction”—i.e., aborting 
some fetuses to increase the chance of positive outcomes for the rest.75 While the 
procedure generally poses little physical risk to the mother, the difficult decision it 
involves can cause severe emotional and family turmoil.76 The decision may be 
most distressing for women carrying triplets, as triplets face an increased risk of 
poor outcomes, but not of the same obvious magnitude as higher-order 
pregnancies.77 
Further, the radically increased medical cost associated with caring for 
twins, triplets, or higher-order pregnancies comes hand-in-hand with the health 
problems linked to multiple births. According to a recent study published in the 
American Journal of Obstetrics and Gynecology, pregnancies resulting in delivery 
of twins are about five times more expensive than a singleton pregnancy.78 
However, even more alarming is that higher-order pregnancies resulting in the 
delivery of triplets or more are 20 times more expensive than a singleton 
pregnancy.79 By the numbers, a typical singleton pregnancy costs about $21,000, a 
pregnancy resulting in twins costs $105,000, and a pregnancy resulting in triplets 
or more costs a staggering $400,000.80 While expenses for singletons are largely 
maternal-related, costs for multiples skew heavily toward infant-related care.81 
                                                                                                                
 72. Multiples: Twins, Triplets and Beyond, supra note 66 (citing AM. COLL. OF 
OBSTETRICIANS & GYNECOLOGISTS, ACOG PRACTICE BULL. NO. 56: MULTIPLE GESTATION: 
COMPLICATED TWIN, TRIPLET, AND HIGHER-ORDER MULTIFETAL PREGNANCY (2004)). 
 73. See id.; Roxanne Patel Shepelavy, When Fertility Treatments Become 
Frightening, SELF, April 2009, available at http://www.self.com/health/2009/04/multifetal-
reduction. 
 74. See Shepelavy, supra note 73. 
 75. See id. (“A fairly simple procedure, reduction poses few risks to the mother 
and is usually recommended by high-risk obstetricians to avoid the dangers of multiples: 
potentially deadly blood pressure swings and a higher chance of gestational diabetes, 
anemia and kidney infections for the mom; prematurity, cerebral palsy or death shortly after 
birth for the babies.”). 
 76. See id. (discussing the difficult decisions women pregnant with high-order 
multiples must make regarding multifetal reduction. On one side of the decision, a better 
chance at normal lives for the remaining fetuses, on the other, deciding to undergo an 
abortion procedure, often in violation of closely held family or religious beliefs.). 
 77. See id. (discussing the difficulty of counseling women carrying triplets on 
reduction, noting that many women know families with healthy triplets, introducing 
anecdotal evidence that may make weighing the risks more difficult). 
 78. Elkin V. Lemos et al., Healthcare Expenses Associated with Multiple vs. 
Singleton Pregnancies in the United States, 209 AM. J. OBSTETRICS & GYNECOLOGY 586.e1 
(2013). 
 79. Id. 
 80. Id. 
 81. Id. at 586.e4 (“For singleton pregnancy, maternal expenses accounted for 
approximately 60% of overall cost, whereas, for twins or higher order multiple births, 
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Given the cost distribution, it comes as little surprise that multiples were 
considerably more likely than singletons to require admission to the neonatal 
intensive care unit (“NICU”) after delivery.82 Overall, the increased costs resulted 
from a wide variety of factors including increased use of the NICU, heavy use of 
Caesarean section for delivery, and longer overall hospital stays for both the 
mother and infants.83 
The data presented above has made it increasingly clear that fertility 
treatment of any kind increases the chance of a multiple—and especially high-
order multiple—pregnancy. Currently, however, because ovulation stimulation is 
not recorded nationally, it is not possible to determine accurately what percentage 
of multiple births result from ovulation induction or ART.84 Nonetheless, there is a 
general medical consensus that only about 20% of triplet or higher-order 
pregnancies result from natural conception.85 Triplets are conceived naturally in 
only about 1 in 10,000 pregnancies.86 Higher-order pregnancies are extremely rare 
in natural conception.87 Thus, the unique and significant risks posed by carrying 
three, four, or even more babies to term can be almost exclusively attributed to the 
rise of ART.88 While a responsible fertility clinic can mitigate some of the risks 
associated with multiple-pregnancy by transferring fewer embryos during IVF,89 
the risk of a high-order pregnancy is not so easily mitigated for patients using 
fertility drugs alone.90 Moreover, not every clinic is responsible. Many choose to 
implant far more embryos than is recommended by the American Society for 
Reproductive Medicine, which, as a result, raises the likelihood of high-order 
multiple pregnancies.91 
                                                                                                                
expenses for infant care accounted for approximately 70% and 85% of total expenses, 
respectively.”). 
 82. Id. at 586.e3 (“Infants of twins or triplets or more were more likely to be 
admitted to NICU and had a higher mortality rate compared with infants of singletons 
(47.7% [triplets or more] vs 24.2% [twins] and 2.9% [singletons]; 2.0% [triplets or more] vs 
0.5% [twins] and 0.06% [singletons]; all P < .0001.”). 
 83. Id. at 586.e4. 
 84. Id. at 586.e2. 
 85. Id. (citing Practice Committee of American Society for Reproductive 
Medicine, Multiple Gestation Associated with Infertility Therapy: An American Society for 
Reproductive Medicine Practice Committee Opinion, 97 J. FERTILITY & STERILITY 825 
(2012)). 
 86. AM. SOC’Y FOR REPRODUCTIVE MED., MULTIPLE PREGNANCY AND BIRTH: 
TWINS, TRIPLETS, AND HIGH-ORDER MULTIPLES: A GUIDE FOR PATIENTS (2012), available at 
http://www.asrm.org/BOOKLET_Multiple_Pregnancy_and_Birth/. 
 87. Id. 
 88. See Schieve et al., supra note 58 (“The striking increase in multiple births in 
the United States in recent decades is attributed primarily to infertility treatments that 
include ovulation stimulation medications.”). 
 89. See Shepelavy, supra note 73 (discussing the American Society for 
Reproductive Medicine’s guidelines that recommend implantation of one embryo for 
women under 30 and two for women 30–35). 
 90. See id. (discussing the difficulty in accurately determining the number of 
eggs released and fertilized after using ovulation stimulation drugs). 
 91. Naomi R. Cahn & Jennifer M. Collins, Eight is Enough, 103 NW. U. L. REV. 
COLLOQUY 501, 502–03 (2009) (discussing the case of the now-famous “Octomom,” Nadya 
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B. The Dangers of IVF and ICSI: Birth Defects and Genetic Considerations 
IVF, and its subcategory ICSI, have come under increased scrutiny as 
recent studies show links between the procedures and higher risks of birth defects 
and other health problems in children.92 Unfortunately, it can now be fairly 
concluded that children conceived in the laboratory are more likely to suffer from 
congenital birth defects and other health problems than those conceived 
naturally.93 The defects can be severe. Canadian researchers concluded that 
children “conceived with use of IVF/ICSI have three times as high a risk of a 
congenital heart defect as naturally conceived infants.”94 A recent study published 
in 2012 illustrates the scale of the risks and remaining uncertainty that surrounds 
ART. The study, a meta-analysis published by Juan Wen and colleagues in the 
Journal of Fertility and Sterility,95 specifically examined epidemiological data that 
assessed the risk of birth defects after ART, and compared that data to the risk 
difference of birth defects after ICSI and IVF.96 The results of the study suggest 
that “there is a significantly increased risk of birth defects in infants conceived by 
ART, but ICSI did not increase the risk compared with [traditional] IVF.”97 
However, the study focused only on birth defects, and did not evaluate the genetic 
concerns, particularly those unique to ICSI, such as the transmission of genetic 
mutations that cause male infertility.98 Moreover, as a meta-study, it is not entirely 
clear to what extent the authors were able to adjust for risk factors such as 
maternal age. Regardless, the authors concluded that, compared to a spontaneous 
                                                                                                                
Suleman. Suleman was a 33-year-old unemployed woman, who at the time of undergoing 
fertility treatment was already caring for six children. Nonetheless, “[t]he fertility clinic that 
treated Suleman agreed to implant her with at least six embryos during an in vitro 
fertilization (IVF) procedure.” Suleman later gave birth to octuplets in early 2009 and has 
been a media sensation ever since). 
 92. See, e.g., Marilynn Marchione, Birth Defect Risk Rises with Some Fertility 
Treatments, TODAY (May 5, 2012, 11:42 AM), 
http://www.today.com/id/47305522/ns/today-today_health/t/birth-defect-risk-rises-some-
fertility-treatments/#.VOeQajofw6U. 
 93. See Juan Wen et al., Birth Defects in Children Conceived by In Vitro 
Fertilization and Intracytoplasmic Sperm Injection: A Meta-Analysis, 97 FERTILITY & 
STERILITY 1331 (2012) (evaluating 56 previous studies and concluding that children 
conceived by IVF and ICSI are at “significantly increased risk for birth defects). 
 94. Shi Wu Wen et al., A Comprehensive Assessment of Outcomes in 
Pregnancies Conceived by In Vitro Fertilization/Intracytoplasmic Sperm Injection, 150 
EUR. J. OBSTETRICS & GYNECOLOGY & REPROD. BIOLOGY 160, 161–62 (2010) (noting that 
heart defects were not minor and were not likely to be associated with prematurity). 
 95. See Juan Wen et al., supra note 93. 
 96. Id. at 1333. 
 97. See id. 
 98. See The Practice Comm. of the Am. Soc’y for Reproductive Med. & Practice 
Comm. of the Soc’y for Assisted Reproductive Tech., Genetic Considerations Related to 
Intracytoplasmic Sperm Injection (ICSI), 86 FERTILITY & STERILITY Suppl. 4 (2006); Gozde 
Zorlu, IVF Boys Have Shorter Fingers, May Have Fertility Problems, BIONEWS (Feb. 15, 
2010), http://www.bionews.org.uk/page_54590.asp. 
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conception, IVF and ICSI significantly increased the risk of birth defects in 
children.99 
Studies increasingly show that the phenomenal explosion in ICSI may be 
primarily responsible for causing birth defects, though there remains some 
uncertainty as to what extent parental factors are to blame.100 Since ICSI involves 
the direct injection of sperm into an egg—even though that sperm would have 
likely been too weak to fertilize the egg without medical intervention—some 
researchers understandably became concerned about the health risks of the 
procedure shortly after it was invented.101 Despite these common-sense fears, there 
was no experimental phase of testing for the ICSI procedure before it was 
introduced for human use.102 This was due, at least in part, to the immediate 
clinical success of the procedure in producing live births.103 Additionally, some 
early studies generally did not show a significantly increased risk of birth defects 
with either IVF or ICSI.104 Perhaps unsurprisingly, much of this early research was 
plagued by methodological problems including small sample sizes and inconsistent 
definitions for major birth defects.105 As researchers Jennifer Kurinczuk and Carol 
Bower found, such deficiencies may have led to an underestimation of the relative 
prevalence of birth defects among infants conceived with assisted reproductive 
technology.106 
A 2012 study by Michael Davies, published in the New England Journal 
of Medicine, found that only ICSI, and not traditional IVF, was associated with a 
                                                                                                                
 99. Juan Wen et al., supra note 93; see also Maryse Bonduelle et al., A Multi-
Centre Cohort Study of the Physical Health of Five-Year-Old Children Conceived After 
Intracytoplasmic Sperm Injection, In Vitro Fertilization and Natural Conception, 20 HUM. 
REPROD. 413 (2004) (concluding that children conceived via ICSI, and to a lesser extent 
IVF, experienced more birth congenital malformations than naturally conceived children 
and were more likely to need healthcare resources); Michele Hansen et al., The Risk of 
Major Birth Defects After Intracytoplasmic Sperm Injection and In Vitro Fertilization, 346 
NEW ENG. J. MED. 725 (2002) (“Infants conceived with use of intracytoplasmic sperm 
injection or in vitro fertilization have twice as high a risk for a major birth defect as 
naturally conceived infants.”). 
 100. Practice Comm. of the Am. Soc’y for Reproductive Med. & Practice Comm. 
of the Soc’y for Assisted Reproductive Tech., supra note 98. 
 101. See Jim M. Cummins & Anne M. Jequier, Concerns and Recommendations 
for Intracytoplasmic Sperm Injection (ICSI) Treatment, 10: Suppl. 1 HUM. REPROD. 138 
(1995); Christopher J. de Jonge & Jessica Pierce, Intracytoplasmic Sperm Injection–What 
Kind of Reproduction is Being Assisted?, 10 HUM. REPROD. 2518 (1995). 
 102. See Anne Drapkin Lyerly, Marking The Fine Line: Ethics and the Regulation 
of Innovative Technologies in Human Reproduction, 11 MINN. J. L. SCI. & TECH. 685, 688 
(2010) (citing Ryuzo Yanagimachi, Is an Animal Model Needed for Intracytoplasmic Sperm 
Injection (ICSI) and Other Assisted Reproduction Technologies?, 10 HUM. REPROD. 2525, 
2526 (1995); Egbert R. te Velde et al., Commentary, Concerns About Assisted 
Reproduction, 351 LANCET 1524, 1524 (1998)). 
 103. Id. 
 104. See Hansen et al., supra note 99. 
 105. Id. 
 106. Id. (citing Jennifer J. Kurinczuk & Carol Bower, Birth Defects in Infants 
Conceived by Intracytoplasmic Sperm Injection: An Alternative Interpretation, 315 BMJ 
1260 (1997)). 
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statistically significant increase in birth defects.107 The study analyzed data from 
birth registries and clinics in southern Australia and utilized advanced statistical 
techniques to isolate the procedural risks associated with different forms of 
ART.108 In contrast to the meta-analysis offered by Juan Wen, the New England 
Journal of Medicine study concluded that “the increased risk of birth defects 
associated with [traditional] IVF was no longer significant after adjustment for 
parental factors.”109 So while the study suggested that both IVF and ICSI were 
associated with a higher risk of birth defects when compared to spontaneous 
conception, once the data was adjusted for maternal age and other parental risk 
factors, only the ICSI correlation remained.110 The results suggest that increased 
risk of birth defects is plausibly linked to the ICSI procedure itself,111 but that 
“differences in male infertility factors that lead to the use of ICSI may also 
underlie the association.”112 Nonetheless, the magnitude of the risk appears to be 
substantial. The results of the New England Journal of Medicine study show that, 
before adjusting for factors such as maternal age, IVF was associated with a 26% 
increase in birth defects compared with spontaneous conception, while ICSI was 
associated with a staggering 77% increase.113 After adjustment, the increased risk 
for traditional IVF largely disappeared, but ICSI was still associated with a 
roughly 57% increase in birth defects114—these numbers suggest that ICSI may be 
associated with a far greater birth-defect risk than what was previously believed. 
For example, an earlier German study found that before adjustment, ICSI was 
associated with only a roughly 44% increase in birth defects as compared to 
spontaneously conceived children.115 
The New England Journal of Medicine study also revealed additional 
insight into the world of ART and the women who undertake it. The authors note 
that women who used ART were more likely to be older, white, affluent, and 
                                                                                                                
 107. See Michael Davies et al., Reproductive Technologies and the Risk of Birth 
Defects, 366 NEW ENG. J. MED. 1803 (2012). 
 108. See id. 
 109. Id. 
 110. Id. at 1809 (“After multivariate adjustment, the association between IVF and 
the risk of any birth defect was no longer significant, whereas the increased risk of any birth 
defect associated with ICSI remained significant.”). 
 111. Id. (citing Bonduelle et al., supra note 99; Jennifer J. Kurinczuk, Safety 
Issues in Assisted Reproduction Technology: From Theory to Reality – Just What Are the 
Data Telling Us About ICSI Offspring Health and Future Fertility and Should We Be 
Concerned?, 18 HUM. REPROD. 925 (2003)). 
 112. Id. 
 113. Id. at 1803 (“The corresponding odds ratios [before and after adjustment for 
risk factors such as maternal age] with in vitro fertilization (IVF) (165 birth defects, 7.2%) 
were 1.26 (95% CI, 1.07 to 1.48) and 1.07 (95% CI, 0.90 to 1.26), and the odds ratios with 
intracytoplasmic sperm injection (ICSI) (139 defects, 9.9%) were 1.77 (95% CI, 1.47 to 
2.12) and 1.57 (95% CI, 1.30 to 1.90).”). 
 114. Id. (“The increased risk of birth defects associated with IVF was no longer 
significant after adjustment for parental factors.”). 
 115. See Alexander Katalinic et al., Pregnancy Course and Outcome After 
Intracytoplasmic Sperm Injection: A Controlled, Prospective Cohort Study, 81 FERTILITY & 
STERILITY 1604 (2004) (finding a relative risk of 1.44 before adjustment for risk factors). 
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nulliparous than women who conceive spontaneously.116 Moreover, their children 
were more likely to be stillborn, delivered by Cesarean section, and have a lower 
mean birth weight than naturally conceived children.117 These observations are 
consistent with previous studies, which also found that pregnancies achieved after 
ICSI resulted in “a higher number of preterm and low birth weight children.”118 
On a slightly unrelated note, one of the most interesting aspects of the 
study involved a comparison of outcomes between frozen embryos and fresh 
embryos in traditional IVF and ICSI.119 For both IVF and ICSI, the researchers 
surprisingly “found a significant increase in the risk of birth defects associated 
with fresh-embryo cycles but not with frozen-embryo cycles.”120 Although the 
study admittedly utilized a small sample size, the results suggest that using frozen 
embryos may be safer than using fresh ones in both IVF and ICSI.121 The authors 
explored several possible explanations, including “a reduced likelihood that 
developmentally compromised embryos will survive the thawing process and the 
temporal separation of the developing embryo from exposure to hormonal 
stimulation drugs.”122 
More importantly, the risk of ICSI is distinguished from that of traditional 
IVF by unique genetic considerations associated with the removal of natural 
selection from the fertilization process. Some of these genetic risks, especially 
those relating to passing down infertility, may not manifest themselves until later 
in life—and thus escape analysis in most studies of IVF outcomes.123 A recent 
study of boys conceived through ICSI suggests that they may have shorter fingers 
than their peers, a metric that is commonly associated with fertility problems.124 
These revelations are particularly concerning given the rapid increase in the 
number of couples undergoing IVF,125 and the proliferation of ICSI as the most 
popular method of IVF.126 Recently, ICSI inventor Andre Van Steirteghem quite 
shockingly came out and publicly urged against ICSI’s widespread use, citing 
concerns that defective sperm may allow genetic disorders to be passed on to the 
                                                                                                                
 116. See Davies et al., supra note 107, at 1805. 
 117. Id. 
 118. Katalinic et al., supra note 115. 
 119. See id. 
 120. See Davies et al., supra note 107, at 1810. 
 121. Id. (noting, however, that the risk of birth defects with fresh cycles of IVF 
was “significantly lower” than the risk with fresh cycles of ICSI). 
 122. Id. at 1811. 
 123. See David Derbyshire, Infertility Time Bomb: IVF Children Have Higher 
Risk of Infertility, Obesity, and Diabetes, DAILY MAIL (Feb. 22, 2010), 
http://www.dailymail.co.uk/health/article-1252901/Infertility-time-bomb-IVF-children-
higher-risk-infertility-obesity-diabetes.html (noting that the increased number of multiples 
resulting from IVF pregnancies puts them at risk for problems later in life); Zorlu, supra 
note 98 (noting that the boys in the study were still too young to test for infertility directly). 
 124. Id. 
 125. See 2011 ART REPORT, supra note 33 (indicating that there were over 
150,000 ART cycles performed in the United States during 2011). 
 126. See id. (ICSI made up 67% of all IVF procedures performed in the United 
States in 2011). 
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next generation.127 Specifically, Professor Van Steirteghem warned that problems 
like diabetes, heart disease, and obesity could be passed on to future generations 
through defective sperm.128 In his view, the ICSI procedure should be reserved for 
only those situations where more traditional methods of IVF have failed.129 
However, responsible voices opposed to the proliferation of ICSI are at 
odds with powerful market forces behind its growth into the new mainstay 
procedure of a multibillion-dollar industry. Early studies suggested that ICSI was 
capable of higher fertilization rates than traditional IVF and that was all that 
mattered.130 While there may be some truth in those results,131 the modern 
consensus is that ICSI does not improve outcomes in cases of unexplained 
infertility or advanced maternal age, and that its routine use should be confined to 
treating male factor infertility.132 
In the United States, the government tracks fertilization and live-birth 
rates for each individual ART clinic.133 These statistics are public and permit direct 
comparison and competition between clinics, allowing patients to shop around for 
the clinic with the highest “success” rates. Given that IVF is only available to 
those in the United States who can pay for it privately,134 clinics necessarily 
compete for a limited pool of patients. In this environment, posting a higher 
success rate than one’s competitors can have a significant impact on a clinic’s 
bottom line.135 In light of these perverse incentives, perhaps most troubling is that 
                                                                                                                
 127. Maren Urner, IVF Technique Is Overused, Says Its Inventor, BIONEWS (Mar. 
1, 2010), http://www.bionews.org.uk/page_55180.asp (speaking at this year’s conference 
for the Advancing Science Serving Society (ASSS), Professor van Steirteghem highlighted 
“the possibility that the direct injection of sperm into the egg, a technique known as 
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that problems like diabetes, heart disease and obesity could be passed on to future 
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 128. Id. (referring to comments made by Professor Andre Van Steirteghem at the 
2010 conference for ASSS). 
 129. Id. 
 130. See, e.g., Gloria Calderón et al., Intracytoplasmic Sperm Injection Versus 
Conventional In-Vitro Fertilization: First Results, 10 HUM. REPROD. 2835 (1995); Dianna 
Payne et al., Successful Treatment of Severe Male Factor Infertility in 100 Consecutive 
Cycles Using Intracytoplasmic Sperm Injection, 9 HUM. REPROD. 2051 (1994). 
 131. Practice Comms. of the Am. Soc’y for Reprod. Med. & Soc’y for Assisted 
Reprod. Tech., Intracytoplasmic Sperm Injection (ICSI) for Non-Male Factor Infertility: A 
Committee Opinion, 98 FERTILITY & STERILITY 1395, 1397 (2012) (conceding that “ICSI 
can increase fertilization rates when lower than expected or failed fertilization has 
previously occurred with conventional insemination”). 
 132. See id. (summarizing the conclusions of the Committee). 
 133. See 2011 ART REPORT, supra note 33 (presenting success rates by age group 
for each of 450 fertility clinics tracked in the United States). 
 134. See PARKER, supra note 19, at 50. 
 135. Patients seeking fertility treatments that often cost in excess of $10,000 per 
attempt have strong incentives, both financial and emotional, to choose a clinic with a rate 
of successful births per cycle of treatment. Because the CDC makes these success rates 
public, they serve as a de facto ranking system for fertility clinics. See 2011 ART REPORT, 
supra note 33. Much as colleges and professional schools are ranked by U.S. News & World 
Report, so are clinics ranked by their success rates. Every clinic fights to post better 
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ICSI’s rapid rise could reflect overuse of the procedure and inadequate disclosure 
of the procedure’s risks to patients. But once the initial studies reported higher 
live-birth rates associated with ICSI, those other concerns were quickly swept 
under the rug by the fertility industry. 
III. CURRENT LEGAL AND REGULATORY OVERSIGHT OF ASSISTED 
REPRODUCTIVE TECHNOLOGY 
A. Regulations Barely Exist and Voluntary Guidelines Do Not Work 
Modern assisted reproduction is a multibillion dollar industry136 that 
affects hundreds of thousands of people every year in the United States. However, 
despite its size and rapid growth, the fertility industry is subject only to very 
limited state and federal regulation.137 While some industry groups have 
promulgated responsible guidelines for the use of assisted reproductive 
technologies, the absence of viable enforcement mechanisms leaves many clinics 
subject only to self-regulation or, in some cases, the enforcement of more general 
laws by the courts.138 Moreover, a comparison of the American Society for 
Reproductive Medicine’s United States guidelines to those issued by the 
organization’s counterpart in the United Kingdom suggests that the United States 
guidelines are somewhat less stringent. ART’s meteoric rise strongly suggests that 
it will play an increasingly important role in reproduction for future generations. 
Nonetheless, law has lagged far behind this groundbreaking technology in the 
United States. Today, for example, the IVF industry mostly operates as a free 
market and there is little that restricts or controls choices made by physicians, 
patients, or donors.139 
ART exists largely outside the current reach of federal regulatory powers. 
Professor Anne Drapkin Lyerly concludes that this may partly be the result of the 
dissociation of innovation in reproductive medicine from experimentation.140 
Generally, federally funded medical researchers are subject to significant 
regulation and oversight by the Department of Health and Human Services 
(“DHHS”).141 However, the U.S. government’s reluctance to fund research on 
embryos and reproductive medicine has seriously eroded any oversight or 
regulatory ability that DHHS could have had over ART.142 In 1994, President 
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Clinton declared that federal funding should not be made available for research 
involving the creation or destruction of embryos.143 Shortly thereafter in 1996, 
Congress began attaching a rider to DHHS appropriations bills that effectuated the 
presidential declaration.144 Thus, Lyerly argues that the absence of federal funding 
in the field of assisted reproduction helps explain ICSI’s “curious” evolution: 
Because scientifically rigorous development and refinement of ICSI 
would have involved the creation, destruction, and discarding of 
embryos, research involving this technique would not have been 
eligible for federal funding. As such, the technology advanced 
rapidly with neither federal funding, nor the scientific scrutiny or 
human subjects’ protections that accompany it.145 
As the comment suggests, Congress’s fear of political controversy created a 
vacuum of federal oversight, and in turn played a major role in ICSI’s quick 
transition from experimental procedure to mainstay of the IVF industry. 
Other federal agencies only possess limited regulatory oversight of the 
assisted reproduction industry. The Food and Drug Administration (“FDA”) has 
largely steered clear of directly regulating assisted reproduction, and has only 
recently engaged in limited regulation surrounding cloning146 and the classification 
of medical devices used in the assisted reproduction.147 By contrast, the CDC has 
been at least somewhat involved in regulating ART and the fertility industry. The 
CDC has statutory authority to regulate pursuant to the Fertility Clinic Success 
Rate and Certification Act.148 However, CDC regulation concerns only the 
certification of laboratories and the reporting of pregnancy success rates achieved 
by fertility clinics utilizing ART.149 While the Fertility Clinic Success Rate and 
Certification Act provides some basic (but voluntary) reporting of clinics’ 
advertising claims, thus far the federal government has not attempted to effectuate 
mandatory regulation of the fertility industry’s use of ART in the United States.150 
State regulation of ART is similarly undeveloped, providing little 
substance to fill the void left by the absence of federal legislation. Most states have 
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not attempted to regulate the fertility industry’s use of ART or its advertisement.151 
However, a few states have taken a more aggressive approach, enacting statutes 
that govern issues such as insurance coverage and disclosure requirements.152 
Virginia, for example, requires fertility clinics to disclose a variety of success 
metrics to patients before performing fertility treatments.153 However, noticeably 
absent from the statute is any specific, mandatory disclosure of the health risks 
associated with fertility drugs, IVF, or ICSI. 
Presumably, the general tort-law doctrine of informed consent would 
operate to require disclosures regarding risks, but it is far from obvious whether 
proper disclosures and truly informed consent occurs under the current relaxed 
regulatory regime. In 1996, a joint council of the American Medical Association 
(“AMA”) issued a report that identified several serious ethical violations within 
the practice of assisted reproduction.154 The report characterized these violations as 
“subtle deception,” and noted “deceptive advertising and insufficient informed 
consent are probably the most common manifestations of this type of ethical 
violation.”155 The report recommended stricter adherence to ethical guidelines and 
increased self-regulation, but stopped short of calling for a legislative solution to 
the unethical practices plaguing the industry.156 Nonetheless, despite the absence 
of legislation, some patients have been able to maintain causes of action against 
clinics that employ deceptive marketing under more general consumer-protection 
laws.157 
In sum, legislation addressing the concerns raised by ART has not been 
forthcoming, and today the United States is unquestionably a “guideline” country. 
The majority of existing assisted-reproduction regulation takes the form of 
professional guidelines published by the American Society for Reproductive 
Medicine (“ASRM”).158 While the ASRM guidelines cover a variety of important 
issues relating to both sound clinical and ethical practice, they have nonetheless 
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faced criticism from commentators.159 Perhaps the most poignant criticism is that 
the guidelines have no teeth because the ASRM do not provide any approved 
protocols that must be followed—in fact, adherence to the guidelines is voluntary, 
subject to the discretion of the individual physician.160 As such, the usefulness of 
ASRM guidelines to mitigate the negative effects of the profit motive is suspect at 
best. 
The only real avenue of enforcement for ASRM guidelines is through a 
process of clinical certification. The United States Society for Assisted 
Reproduction (“SART”), a subsidiary of ASRM, operates a certificate program for 
clinics that adhere to ASRM minimum guidelines, maintain high ethical standards, 
and report annual data to SART.161 However, there is no requirement that a clinic 
be SART certified to operate in the United States.162 As a result, while SART can 
revoke its certification from a rogue clinic,163 such a clinic may continue to operate 
and many customers would never notice the difference. Roughly 10% of all 
fertility clinics in the United States are not SART certified.164 Thus, consider that, 
while the ASRM recommends that no more than two embryos be implanted in a 
woman younger than age 35,165 there is no explicit mechanism to compel 
adherence to this guideline, and as a result it may be easily violated. This is hardly 
the robust “written commitment to ethical principles” that the 1996 AMA joint 
committee envisioned to be the optimal self-regulatory solution to ethical lapses in 
the practice of assisted reproduction.166 Moreover, it highlights that the guidelines 
are an ineffective regulatory mechanism to protect patients. Finally, as one 
commentator points out, even if the guidelines were enforceable, they are directed 
toward the fertility profession, and unlike other regulated industries, they do not 
enjoy any input from the public or disciplines outside of law and medicine.167 
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B. Foreign Approaches 
Many other countries have taken a much more aggressive approach in 
regulating ART. A 2010 survey conducted by the International Federation of 
Fertility Societies examined ART regulation in 107 countries and found that 42% 
employed legislative regulation of ART.168 Previously, this proportion was larger, 
but the change was likely a result of the first-time inclusion of many developing 
countries in the 2010 survey.169 Over 40 countries, including most of Europe, have 
enacted specific legislation that regulates the use of ART.170 Twenty-six countries, 
including the United States, have only voluntary guidelines in place.171 Two-thirds 
of the countries with enacted legislation have some version of a licensing 
requirement, and many are quite stringent.172 For example, in Australia, the penalty 
for operating a non-accredited facility is up to ten years in prison, a far cry from 
the voluntary certification requirements imposed by SART in the United States.173 
The United Kingdom has perhaps the most well-developed system of 
ART regulation and should be used as a model for what is necessary in America. 
The Human Fertilisation and Embryological Authority (“HFEA”) has several key 
responsibilities, including issuing licenses to IVF clinics and other establishments 
carrying out embryo research. It also regulates the storage of gametes and 
embryos, and implements the directives of the European Union relating to ART.174 
The HFEA requires that before a license will be issued, all clinics must 
demonstrate that they can comply with the “Code of Practice.”175 The Code is 
frequently updated and covers “all details of the clinical and embryological 
practice associated with assisted reproductive technology.”176 While at first glance 
this might seem similar to the U.S. guidelines system, it differs greatly because 
licensure is mandatory in the United Kingdom and clinics cannot operate “outside” 
the Code.177 In addition to the independent HFEA, the National Institute for Health 
and Clinical Excellence (“NICE”), part of the National Health Service, publishes 
guidelines for providers to complement the regulations promulgated by the 
HFEA.178 
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Comparison of the U.S.’s ASRM guidelines and the U.K.’s NICE 
guidelines reveals that the ASRM guidelines allow for the transfer of greater 
numbers of embryos to women undergoing IVF than their NICE counterparts. For 
a woman’s first cycle, the ASRM recommends the transfer of one to two high-
quality cleavage-stage embryos for women under 35, two for women 35–37, three 
for women 38–40, and five for women 41 and older.179 If the patient has already 
gone through one unsuccessful cycle, the ASRM then recommends two embryos 
for women under 35, three for women 35–37, four for women 38–40, and five for 
women over 41.180 This is in stark contrast to NICE’s far more conservative 
approach. NICE recommends that in the first cycle of treatment, clinics transfer 
only one embryo for women under 37.181 Even after an unsuccessful cycle (or 
two), the NICE guidelines strongly suggest transferring only a single high-quality 
embryo, and never more than two.182 For older women, the NICE guidelines 
suggest that no more than two embryos be transferred.183 This conservative 
approach to IVF is an explicit attempt by the British government to decrease the 
incidence of costly multiple births.184 As multiple births are significantly more 
costly than singletons,185 this is an issue of obvious importance in a socialized 
healthcare system. It is also especially relevant given that Europeans use ART 
services at twice the rate of Americans.186 Some European countries, for instance 
Germany, set explicit legal maximums on the number of embryos that may be 
transferred in an IVF procedure and consider breach of the law a felony 
violation.187 
Given the differences in legal and regulatory environment, it is not 
surprising that researchers have compared ART outcomes between Europe and the 
United States. In particular, a recent study published in the Journal of Human 
Reproduction explored why IVF patients in the United States have significantly 
higher rates of clinical pregnancy and delivery than European patients.188 The 
study confirms that clinics in the United States transfer a greater number of 
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embryos per ART cycle than their European counterparts.189 Specifically, 
Europeans were far more likely to receive a single or double embryo transfer than 
patients in the United States; and Americans, by contrast, were nearly twice as 
likely as Europeans to receive three or four embryos.190 Unsurprisingly, the study’s 
data also shows that multiple pregnancies were also far more common in the 
United States.191 However, the study’s authors note that the increased number of 
embryos transferred does not alone explain the differences in clinical pregnancy 
rates between the two continents.192 Nonetheless, the authors conclude there are 
substantial differences in the practice of ART between the continents, and “[t]hese 
differences appear primarily driven by greatly diverging regulatory environments 
on both sides of the Atlantic and, at least based on pregnancy rates, do not appear 
to benefit the European population.”193 However, some commentators have been 
critical of this conclusion, specifically noting that Europe’s reduced rate of 
multiple pregnancies evidences the substantial benefits of increased regulation of 
ART.194 
While the United States may never elect to regulate reproductive 
technology to the same extent as witnessed in Europe, the current regulatory void 
and lack of meaningful oversight has contributed to a “wild west” mentality at 
some American IVF clinics.195 In this environment, the profit motive reigns 
supreme, breeding conflicts of interest between clinics and patients, 
institutionalizing practices of subtle deception, and contributing to the health crisis 
of multiple births. A well-functioning free market for ART services depends upon 
consumers having access to the best possible information in order both to make 
informed treatment decisions and to avoid negative outcomes. To the contrary, the 
current regulatory system in the United States has failed to ensure the integrity of 
the informed consent process, and has failed to adequately address the growing 
burden of multiple births. The existing patchwork of voluntary guidelines, state 
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law, and limited federal oversight is not sufficient to ensure the fertility market 
remains free, fair, and safe for the twenty-first century. 
IV. RECOMMENDATIONS FOR LAW AND POLICY REFORM 
It is clear that the meteoric rise of ART has vastly outpaced the 
development of a cohesive legal framework governing its practice. The increasing 
use of IVF, ICSI, and other ART procedures raises important and often emotional 
issues that deserve considered legal and policy solutions. ART is here to stay, and 
it seems likely that the technology will play an increasingly important role in 
human reproduction in the future. As this groundbreaking technology continues to 
advance, the law must keep pace. The current relaxed self-regulation and 
patchwork state law is ineffective at mitigating the conflicts of interest created by 
profit motive in the ART industry. Conceiving a child is an emotional rollercoaster 
for infertile couples; as they look for hope in an otherwise bleak situation, they 
may be especially vulnerable to the “subtle deception” methods that sparked the 
AMA’s concern back in 1996.196 But what can law accomplish, and, perhaps more 
importantly, what should new regulation of ART look like? 
There are several distinct areas of ART that might benefit from increased 
oversight and regulation, but because the existing regulation in both has been 
insufficient to mitigate conflicts of interest in the profit-driven fertility industry, 
two issues deserve special attention: the complications raised by multiple births 
and the specific choice of ART method. 
A. Dealing with Complications Raised by Multiples 
First, we must address the oft-written-about problem of multifetal 
pregnancies as a result of ART. This topic has received much attention over the 
years from commentators, and is an area where many European countries have 
pursued expanded regulation.197 Some commentators have called for increased 
regulation of ovulation-inducing fertility drugs and have even gone so far as to 
suggest their complete prohibition.198 Another outside-the-box idea might be the 
implementation of a tradable “permit system” for multiple pregnancies. This 
permit system could be something akin to the cap-and-trade system used for 
pollutants, but would cap the number of multifetal pregnancies, and would allow 
clinics to purchase permits allowing them to provide treatments likely to result in 
multiple pregnancies.199 This idea, Richard Hawkins suggests, would force 
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interested parties to internalize the costs of their reproductive choices and, as a 
consequence, reduce the incidence of multiple births and their externalities to the 
healthcare system.200 Still others have suggested a federal law codifying embryo-
transfer limits in the provision of infertility care.201 Such a law would likely 
resemble the mandatory embryo-transfer limits present in some foreign 
countries.202 However, the true goal of any new regulation in this area must be to 
mitigate or displace the incentive structure that pushes for-profit clinics to produce 
pregnancies without considering the risks and costs of a multiple pregnancy. 
B. Influencing the Choice of ART Method 
The second major area deserving regulatory attention is the choice of 
reproductive technology to be utilized by a patient. This issue is of special 
importance given the meteoric rise of ICSI and the abundance of research that 
suggests the procedure may carry greater risks to future children than more 
traditional methods of IVF.203 However, the issues deserving of attention here are 
even broader. Professor Lyerly has suggested a need for a significant revaluation 
of how research is performed in the ART field. Lyerly notes that the challenges of 
regulating ART innovation are separate and distinct from those of regulating the 
practice of ART.204 She proposes that the requirements for informed consent be 
both clarified and standardized, including explicit disclosure and separate 
requirements for participating in research versus standard clinical procedures.205 A 
clear and standardized system for obtaining informed consent would significantly 
benefit clinical practice, and would go a long way to ameliorate the practices of 
subtle deception that undoubtedly still plague the profit-driven fertility industry. 
Any law that will standardize what must be disclosed to ART patients should also 
mandate full disclosure of: (1) the for-profit nature of the fertility clinic; and (2) 
the potential conflict of interest between the clinic (in its desire to post high 
pregnancy and birth rates) and the patient who desires a healthy singleton baby. 
C.  A Measured Regulatory Response 
Finally, it should be noted that not all commentators agree that increased 
regulation of ART is desirable. In fact, Professor Kerry Lynn Macintosh has 
expressed significant reservations about restricting access to ART, warning that 
advocates of increased public oversight “have failed to recognize the eugenic 
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implications of acting to ‘protect’ children from their own existence.”206 She 
worries that regulation of “conventional” technologies like IVF and ICSI could 
have serious eugenic implications, relegating an entire class of people to perpetual 
childlessness.207 
D. Mandated Disclosure and the Regulation of ICSI 
ICSI has transformed assisted reproduction by allowing infertile men the 
chance to reproduce. However, with great technological advances comes risk of 
misuse, and accordingly ICSI’s success at producing live births comes with 
downsides. That said, as ICSI becomes the mainstay of fertility clinics across the 
nation, it is imperative that clinics adequately counsel patients on the risks of the 
procedure, lest patients misconceive ICSI’s popularity for its safety. 
Specifically, truly informed consent requires full and clear disclosure of 
recent research on ICSI’s risks compared to alternative treatment methods. While 
this life-giving advance has helped countless parents over the last 20 years, the 
increasing evidence of its dangers208 should counsel prudence for both patients and 
doctors. Today, researchers agree that the full disclosure of ICSI’s risks—both for 
birth defects and for less obvious long-term genetic problems—should be fully 
disclosed to potential patients.209 
However, ICSI’s rapid takeover of the assisted reproduction market raises 
the possibility that consumers may not currently be operating with full 
information, and raises the likelihood of inadequate informed consent. While the 
CDC’s most recent data from 2011 shows that 67% of IVF cycles involved ICSI in 
United States,210 that number may be much higher in certain states or at individual 
clinics. For example, two-thirds of fertility clinics in Arizona utilize ICSI more 
than 90% of the time.211 While it is not impossible that ICSI’s extensive use simply 
reflects consumer preferences, it seems more plausible that many consumers are 
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simply unaware of the most recent research illustrating the unique risks associated 
with ICSI. 
In light of the risks associated with ICSI, experts in the field—including 
ICSI’s inventor—argue that the process should be reserved for use only when 
absolutely necessary.212 In their view, ICSI should not be the first choice utilized to 
help infertile couples become parents. Thankfully, ICSI’s overuse has not gone 
entirely unnoticed and has recently attracted the scrutiny of U.K. regulators.213 
According to the Independent, Lisa Jardine, chairperson of the U.K.’s HFEA, 
believes that some IVF clinics are using ICSI simply because it is “easier and has a 
lower chance of fertilization failure than standard IVF, rather than because it is in 
the best interests of patients.”214 In Britain, data collected by the HFEA shows that 
30% of ICSI cycles are not related to male infertility—even though male factor 
infertility was the driving force behind its invention. In addition, Allan Pacey, 
chairperson of the British Fertility Society, has confronted the procedure’s overuse 
as well. Pacey suggests that, in light of ICSI’s risks, it should be used only “when 
it’s needed, and not as some kind of guarantee against fertilization failure, which is 
how some clinics approach it.”215 In a similar vein, a group of researchers recently 
concluded that, not only are more stringent criteria desirable to combat ICSI’s 
overuse, but that reserving the procedure for proven applications may not 
negatively affect pregnancy outcomes.216 Regardless, infertility patients deserve 
full disclosure of the risks for the procedures they elect to undertake. 
Jennifer Jurinczuk captured this sentiment succinctly in a 2003 piece for 
the Journal of Human Reproduction: 
Pregnancy is something of a lottery for all couples. However, 
compared with couples who conceive spontaneously, for those who 
require IVF or ICSI the lottery is weighed more heavily against a 
successful outcome at every stage of the process, not just 
conception. This is the reality alongside the hope that must be 
conveyed at counselling to all couples contemplating treatment. 
Indeed this counselling must be sufficiently detailed to ensure that, 
whilst the ICSI procedure itself is regarded as a routine procedure in 
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most IVF clinics, prospective recipients do not equate routine with 
being completely safe and completely risk-free for their offspring.217 
E. Moving Forward into the Future 
In sum, there is no silver bullet to combat infertility. IVF technology has 
come a very long way and provided an entire generation of adults with the chance 
to start a family, but it remains a risky endeavor. Regulations that mandate full 
disclosure of the multitude of risks associated with assisted reproduction are a 
critical starting point in bringing ART regulation into the twenty-first century and 
ensuring that patient consent is truly informed. 
To start, significant reforms must be made to the current patchwork of 
laws governing the use of ART in the United States. ART has evolved at such a 
break-neck pace that it has far outgrown the system of voluntary self-regulation 
and reporting as it currently exists. Moreover, the inconsistent state laws regulating 
ART are far from sufficient and do not supplant the need for nationwide standards. 
Remedying the conflicts of interest that have become ensconced in the practice of 
ART will take a concerted effort by lawmakers and healthcare regulators, and 
cannot be expected to occur without some form of governmental intervention. 
While the exact form that governmental intervention should take remains a topic 
for discussion, the need for clear and ethical practice standards grows ever more 
pressing as ART business booms. But what will regulation of ART in the United 
States look like? 
1. Federal Oversight 
One possibility is that the threat of statutory regulation might be enough 
to coerce the fertility industry to self-regulate better. At least one commentator has 
suggested that the threat of federal legislation on embryo-transfer limits might 
prompt SART and ASRM to adopt “more stringent restrictions with greater 
consequences for noncompliance.”218 In that situation, the option of direct 
regulation would always remain on the table if the threat alone did not lead to the 
desired outcome.219 Such an approach could also be successful in other areas of 
ART regulation. For instance, the threat of explicit federal regulation of the 
informed consent process might prompt ASRM and SART both to standardize the 
informed consent system and to better police clinics’ disclosure practices. The 
threat of legislative action has proven effective in other countries, as it was this 
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sort of regulatory threat that led to the creation of the U.K.’s Voluntary Licensing 
Authority.220 
Regardless, some form of increased federal oversight of the informed 
consent process is likely necessary to ensure that patients are able to make 
decisions about innovative procedures with full knowledge of the risks and 
benefits. Clinics should also be required to disclose to patients both their for-profit 
nature and the potential conflict of interest between the patient and a clinic seeking 
higher pregnancy and birth rates. Disclosure is of special importance with regard 
to novel procedures like ICSI. Despite its widespread use, a growing body of 
research strongly suggests ICSI carries increased risks for children as compared to 
traditional IVF.221 Accordingly, any reform of the informed consent process should 
mandate full disclosure of these risks to prospective patients. Finally, while the 
ASRM guidelines pave the way for a strong self-regulatory regime, they need 
stronger federal enforcement mechanisms in order to mitigate successfully the 
perverse incentives created by the pursuit of profit. 
2. Mandatory Clinic Certification 
Requiring ART clinics to obtain SART certification would go a long way 
in ensuring compliance with ASRM’s ethical and practice guidelines.222 Such a 
move would protect a doctor’s discretion for individual patients’ treatment plans, 
but would also ensure that clinics do not systematically operate outside the 
industry’s accepted ethical norms. 
A strong and enforceable clinic certification system is perhaps the best 
option for addressing the conflicts of interest and ethical shortcomings that have 
long haunted the fertility industry. With mandatory certification come clear and 
enforceable rules that apply the ethical norms of the industry to all clinics. 
Eliminating the ability of IVF clinics to ignore ASRM embryo-transfer guidelines 
is a reasonable first step in addressing the rising costs of multiple births in the 
United States. Similarly, conditioning clinic certification on the implementation of 
a standardized and robust informed consent process would both protect patients 
and prevent clinics from sugar-coating the risks of ART procedures. Whether 
ASRM would be up to the task of significantly strengthening its current SART 
certification system remains to be seen, but mandatory certification of ART 
clinics, either through ASRM or through a federal agency, is a sensible way to start 
regulating ART in the twenty-first century. 
While there are likely dozens of other possible details to work out, there 
is simply no denying that it is well past time for meaningful government 
intervention in the ART industry. 
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CONCLUSION 
The drive to reproduce is at the center of human beings’ survival on this 
planet. Sadly, not all individuals are born equally capable in this quest. For those 
who desperately desire children but cannot have them on their own, the remarkable 
growth of ART over the past few decades has been a transformative innovation. 
Some ten million babies now inhabit the earth because of unbelievable 
breakthroughs in reproductive technology. 
However, pioneering advancements eventually create challenges, and can 
lead to potential abuses if left unchecked. Today, thousands of would-be parents 
are spending their life fortunes on ART without being adequately informed of the 
benefits and risks. The dramatic increase in the use of ICSI during IVF procedures 
is of particular concern, since modern medicine is now capable of fertilizing eggs 
with sperm that would have failed the natural selection process on their own. IVF 
providers face little incentive to impress these risks on their customers, and operate 
in a largely unregulated environment where cash is king. The incentive to report 
high live-birth rates dictated by the profit motive pushes clinics to both implant 
more embryos than necessary and recommend technologies that may increase 
births notwithstanding increased defect rates. 
Law and regulation have lagged far behind technological advances in this 
arena. Their absence has contributed to a “wild west” mentality in some fertility 
clinics, where anything goes if it will make money. It is now past time we act to 
change that reality. At a minimum, stricter federal regulation of the fertility 
industry is necessary to preserve its benefits while mitigating its risks. Truly 
informed consent can only be achieved when patients know exactly what they are 
getting themselves into. Legislation or regulation mandating specific information 
disclosures is necessary because our current system of voluntary guidelines lacks 
teeth and viable enforcement mechanisms. Mandatory fertility clinic certification 
would also ensure that all enterprises are operating on a level playing field, and 
that patients receive standardized information regarding risks and outcomes. 
We are living in a transformative time in the history of human 
reproduction. With common sense regulation to curb potential conflicts and 
abuses, we can ensure that the miracle of parenthood will be available to millions 
more would-be parents in generations to come. 
 
